FDA approves Abbott’s HUMIRA to treat ulcerative colitis

Published on September 29, 2012 at 1:13 AM · No Comments

Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved HUMIRA® (adalimumab) for inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative colitis (UC) when certain other medicines have not worked well enough.  Combined with its approval to treat moderate to severe Crohn's disease, HUMIRA is now approved for the treatment of two primary diseases that comprise inflammatory bowel disease (IBD). 

HUMIRA works by inhibiting tumor necrosis factor-alpha (TNF-alpha).  The UC approval represents the seventh indication for this treatment in the U.S. and makes HUMIRA the first and only self-administered biologic treatment approved for use in this disease.  It is not known if HUMIRA is effective in people with moderate to severe UC who have lost response to or could not tolerate anti-TNF medicines.  HUMIRA can be self-administered after proper injection training is received and with proper physician monitoring.

"There is significant unmet medical need in this patient population, which has not seen a new treatment approved in more than seven years," said William J. Sandborn, M.D., division chief, Gastroenterology, University of California, San Diego.  "This FDA approval is good news for patients and health care professionals who are seeking another option to manage the disease."

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post